NO300972B1 - Analogifremgangsmåte for fremstilling av terapeutisk aktive, kondenserte polysykliske forbindelser - Google Patents
Analogifremgangsmåte for fremstilling av terapeutisk aktive, kondenserte polysykliske forbindelser Download PDFInfo
- Publication number
- NO300972B1 NO300972B1 NO904666A NO904666A NO300972B1 NO 300972 B1 NO300972 B1 NO 300972B1 NO 904666 A NO904666 A NO 904666A NO 904666 A NO904666 A NO 904666A NO 300972 B1 NO300972 B1 NO 300972B1
- Authority
- NO
- Norway
- Prior art keywords
- compound
- formula
- alkyl
- compounds
- ring
- Prior art date
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 15
- 125000003367 polycyclic group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 16
- -1 polycyclic heterocyclic compounds Chemical class 0.000 claims abstract description 13
- 238000002360 preparation method Methods 0.000 claims description 23
- 150000003839 salts Chemical class 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 11
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 239000002585 base Substances 0.000 claims description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 239000003153 chemical reaction reagent Substances 0.000 claims description 4
- 125000006413 ring segment Chemical group 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 150000001266 acyl halides Chemical class 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 150000008044 alkali metal hydroxides Chemical class 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000003118 aryl group Chemical group 0.000 claims description 3
- 230000008878 coupling Effects 0.000 claims description 3
- 238000010168 coupling process Methods 0.000 claims description 3
- 238000005859 coupling reaction Methods 0.000 claims description 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 2
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 2
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 2
- 125000002252 acyl group Chemical group 0.000 claims description 2
- 125000003435 aroyl group Chemical group 0.000 claims description 2
- 125000000623 heterocyclic group Chemical group 0.000 claims description 2
- CTAPFRYPJLPFDF-UHFFFAOYSA-N isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 239000007858 starting material Substances 0.000 claims 3
- 239000000739 antihistaminic agent Substances 0.000 abstract description 5
- 239000005557 antagonist Substances 0.000 abstract description 3
- 229940125715 antihistaminic agent Drugs 0.000 abstract description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 45
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 24
- 108010003541 Platelet Activating Factor Proteins 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000007788 liquid Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 15
- 239000007787 solid Substances 0.000 description 14
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 13
- 239000000843 powder Substances 0.000 description 13
- 210000004623 platelet-rich plasma Anatomy 0.000 description 10
- 239000002775 capsule Substances 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003826 tablet Substances 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- 239000002253 acid Substances 0.000 description 6
- 239000000284 extract Substances 0.000 description 6
- 230000005540 biological transmission Effects 0.000 description 5
- 235000019439 ethyl acetate Nutrition 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- VCORJVHHVZXWQX-UHFFFAOYSA-N 8,9-dihydro-7h-benzo[7]annulene-5,6-dione Chemical compound O=C1C(=O)CCCC2=CC=CC=C21 VCORJVHHVZXWQX-UHFFFAOYSA-N 0.000 description 4
- 241000700198 Cavia Species 0.000 description 4
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000000443 aerosol Substances 0.000 description 4
- 230000002776 aggregation Effects 0.000 description 4
- 238000004220 aggregation Methods 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 239000012458 free base Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 150000002367 halogens Chemical class 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000012299 nitrogen atmosphere Substances 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 229910052938 sodium sulfate Inorganic materials 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 4
- 229920002554 vinyl polymer Polymers 0.000 description 4
- YOLVBJUSDXESQT-LSLKUGRBSA-N (2S)-2-amino-N-(1-diphenoxyphosphorylethyl)propanamide Chemical compound C=1C=CC=CC=1OP(=O)(C(C)NC(=O)[C@@H](N)C)OC1=CC=CC=C1 YOLVBJUSDXESQT-LSLKUGRBSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000000932 sedative agent Substances 0.000 description 3
- 229940125723 sedative agent Drugs 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003848 thrombocyte activating factor antagonist Substances 0.000 description 3
- 230000000699 topical effect Effects 0.000 description 3
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 208000024780 Urticaria Diseases 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 230000008485 antagonism Effects 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000003638 chemical reducing agent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 150000002391 heterocyclic compounds Chemical class 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960004958 ketotifen Drugs 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- KJIFKLIQANRMOU-UHFFFAOYSA-N oxidanium;4-methylbenzenesulfonate Chemical compound O.CC1=CC=C(S(O)(=O)=O)C=C1 KJIFKLIQANRMOU-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- BLSRGJPGRJBHQK-BUSXIPJBSA-N (2s)-2-amino-1-(2-diphenoxyphosphorylpyrrolidin-1-yl)propan-1-one Chemical compound C[C@H](N)C(=O)N1CCCC1P(=O)(OC=1C=CC=CC=1)OC1=CC=CC=C1 BLSRGJPGRJBHQK-BUSXIPJBSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- SYXIINHHRQQNGK-UHFFFAOYSA-N 1,3-thiazol-4-ol Chemical compound [O-]C1=CSC=[NH+]1 SYXIINHHRQQNGK-UHFFFAOYSA-N 0.000 description 1
- IDPURXSQCKYKIJ-UHFFFAOYSA-N 1-(4-methoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C=C1 IDPURXSQCKYKIJ-UHFFFAOYSA-N 0.000 description 1
- GCBKMPNZRQYTHV-UHFFFAOYSA-N 1-[(4-methoxyphenyl)methyl]-2-methyl-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c]imidazol-10-one Chemical compound C1=CC(OC)=CC=C1CN1C(C(=O)C2=CC=CC=C2CC2)=C2N=C1C GCBKMPNZRQYTHV-UHFFFAOYSA-N 0.000 description 1
- YHXIFUAGWZUREF-UHFFFAOYSA-N 1-[4-(2-acetyl-4,5-dihydrobenzo[1,2]cyclohepta[2,4-c]pyrazol-10-ylidene)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1=C1C2=CC=CC=C2CCC2=CN(C(C)=O)N=C21 YHXIFUAGWZUREF-UHFFFAOYSA-N 0.000 description 1
- YOKILSNVHTWOOJ-UHFFFAOYSA-N 1-[4-(2-methyl-2h-benzo[1,2]cyclohepta[3,6-c][1,3]thiazol-10-yl)piperidin-1-yl]ethanone Chemical compound C12=NC(C)SC2=CC=C2C=CC=CC2=C1C1CCN(C(C)=O)CC1 YOKILSNVHTWOOJ-UHFFFAOYSA-N 0.000 description 1
- LEKQWRAITLQPRS-UHFFFAOYSA-N 1-[4-(2-methyl-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c][1,3]oxazol-10-ylidene)piperidin-1-yl]ethanone Chemical compound C1CN(C(=O)C)CCC1=C1C2=CC=CC=C2CCC2=C1N=C(C)O2 LEKQWRAITLQPRS-UHFFFAOYSA-N 0.000 description 1
- WMXPKSVRAZLLQS-UHFFFAOYSA-N 1-benzyl-10-(1-methylpiperidin-4-yl)-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c]pyrazol-10-ol Chemical compound C1CN(C)CCC1C1(O)C2=CC=CC=C2CCC2=C1N(CC=1C=CC=CC=1)N=C2 WMXPKSVRAZLLQS-UHFFFAOYSA-N 0.000 description 1
- VVJQGUSMDLABEG-UHFFFAOYSA-N 11h-benzo[1,2]cyclohepta[3,4-b]pyridine Chemical class C1=CC2=CC=CN=C2CC2=CC=CC=C21 VVJQGUSMDLABEG-UHFFFAOYSA-N 0.000 description 1
- JSJHCLSBJPUCBQ-UHFFFAOYSA-N 18-azatetracyclo[9.7.0.03,8.012,17]octadeca-1(11),3,5,7,12,14,16-heptaen-2-one Chemical compound C1CC2=CC=CC=C2C(=O)C2=C1C1=CC=CC=C1N2 JSJHCLSBJPUCBQ-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- LJCZNYWLQZZIOS-UHFFFAOYSA-N 2,2,2-trichlorethoxycarbonyl chloride Chemical compound ClC(=O)OCC(Cl)(Cl)Cl LJCZNYWLQZZIOS-UHFFFAOYSA-N 0.000 description 1
- ZNJLSMXOKQGNQG-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-(1-acetyl-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c]pyrazol-10-ylidene)piperidine-1-carboxylate Chemical compound C1=2N(C(=O)C)N=CC=2CCC2=CC=CC=C2C1=C1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 ZNJLSMXOKQGNQG-UHFFFAOYSA-N 0.000 description 1
- OSUCRDLRDSVWJW-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-(2-acetyl-4,5-dihydrobenzo[1,2]cyclohepta[2,4-c]pyrazol-10-ylidene)piperidine-1-carboxylate Chemical compound C12=NN(C(=O)C)C=C2CCC2=CC=CC=C2C1=C1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 OSUCRDLRDSVWJW-UHFFFAOYSA-N 0.000 description 1
- MQMOLNCWLKBGNQ-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-(2-methyl-10h-benzo[1,2]cyclohepta[3,4-c][1,3]thiazol-10-yl)piperidine-1-carboxylate Chemical compound C12=CC=CC=C2C=CC=2SC(C)=NC=2C1C1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 MQMOLNCWLKBGNQ-UHFFFAOYSA-N 0.000 description 1
- PJSXLUYECKIICH-UHFFFAOYSA-N 2,2,2-trichloroethyl 4-(2-methyl-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c][1,3]oxazol-10-ylidene)piperidine-1-carboxylate Chemical compound O1C(C)=NC2=C1CCC1=CC=CC=C1C2=C1CCN(C(=O)OCC(Cl)(Cl)Cl)CC1 PJSXLUYECKIICH-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
- QCEHDADBIVGNDY-UHFFFAOYSA-N 2-methyl-10-(1-methylpiperidin-4-ylidene)-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c][1,3]oxazole Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CCC2=C1N=C(C)O2 QCEHDADBIVGNDY-UHFFFAOYSA-N 0.000 description 1
- PDRCYYVPHGZXRY-UHFFFAOYSA-N 2-methyl-4,5-dihydrobenzo[1,2]cyclohepta[3,4-c][1,3]oxazol-10-one Chemical compound C1CC2=CC=CC=C2C(=O)C2=C1OC(C)=N2 PDRCYYVPHGZXRY-UHFFFAOYSA-N 0.000 description 1
- PPFNKAXNPMDRKM-UHFFFAOYSA-N 5-hydroxyimino-8,9-dihydro-7h-benzo[7]annulen-6-one Chemical compound C1CCC(=O)C(=NO)C2=CC=CC=C21 PPFNKAXNPMDRKM-UHFFFAOYSA-N 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- NYUKQQKYLQZQFP-UHFFFAOYSA-N 7-(dimethylaminomethylidene)-8,9-dihydrobenzo[7]annulene-5,6-dione Chemical compound O=C1C(=O)C(=CN(C)C)CCC2=CC=CC=C21 NYUKQQKYLQZQFP-UHFFFAOYSA-N 0.000 description 1
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- SKYGJSSSEJLKFX-UHFFFAOYSA-N C1C(CC(Cl)(Cl)Cl)N(C(=O)O)CCC1=C1C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 Chemical compound C1C(CC(Cl)(Cl)Cl)N(C(=O)O)CCC1=C1C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 SKYGJSSSEJLKFX-UHFFFAOYSA-N 0.000 description 1
- KFJVRRNYVYGNLE-UHFFFAOYSA-N C1CN(C(=O)C)CCC1=C1C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 Chemical compound C1CN(C(=O)C)CCC1=C1C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 KFJVRRNYVYGNLE-UHFFFAOYSA-N 0.000 description 1
- AYVXNINZQIRBGG-UHFFFAOYSA-N C1CN(C)CCC1C1(O)C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 Chemical compound C1CN(C)CCC1C1(O)C2=CC=CC=C2CCC2=C1NC1=CC=CC=C12 AYVXNINZQIRBGG-UHFFFAOYSA-N 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- VXCUURYYWGCLIH-UHFFFAOYSA-N Dodecanenitrile Chemical compound CCCCCCCCCCCC#N VXCUURYYWGCLIH-UHFFFAOYSA-N 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- RYECOJGRJDOGPP-UHFFFAOYSA-N Ethylurea Chemical compound CCNC(N)=O RYECOJGRJDOGPP-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZSXGLVDWWRXATF-UHFFFAOYSA-N N,N-dimethylformamide dimethyl acetal Chemical compound COC(OC)N(C)C ZSXGLVDWWRXATF-UHFFFAOYSA-N 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000036428 airway hyperreactivity Effects 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940124326 anaesthetic agent Drugs 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001430 anti-depressive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 229940005513 antidepressants Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 235000021311 artificial sweeteners Nutrition 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000004044 bronchoconstricting agent Substances 0.000 description 1
- 230000003435 bronchoconstrictive effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003874 central nervous system depressant Substances 0.000 description 1
- 238000000262 chemical ionisation mass spectrometry Methods 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- WGLUMOCWFMKWIL-UHFFFAOYSA-N dichloromethane;methanol Chemical compound OC.ClCCl WGLUMOCWFMKWIL-UHFFFAOYSA-N 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 238000002451 electron ionisation mass spectrometry Methods 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229960002598 fumaric acid Drugs 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000011874 heated mixture Substances 0.000 description 1
- 239000008240 homogeneous mixture Substances 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- IHLVCKWPAMTVTG-UHFFFAOYSA-N lithium;carbanide Chemical compound [Li+].[CH3-] IHLVCKWPAMTVTG-UHFFFAOYSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- DKUHVHBMOIMMIO-UHFFFAOYSA-L magnesium;1-methylpiperidine;dichloride Chemical compound [Mg+2].[Cl-].[Cl-].CN1CCCCC1 DKUHVHBMOIMMIO-UHFFFAOYSA-L 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 229940098895 maleic acid Drugs 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229940099690 malic acid Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 125000002524 organometallic group Chemical group 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- JOVOSQBPPZZESK-UHFFFAOYSA-N phenylhydrazine hydrochloride Chemical compound Cl.NNC1=CC=CC=C1 JOVOSQBPPZZESK-UHFFFAOYSA-N 0.000 description 1
- 229940038531 phenylhydrazine hydrochloride Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000005057 refrigeration Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 230000016160 smooth muscle contraction Effects 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 125000001302 tertiary amino group Chemical group 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012956 testing procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 230000008728 vascular permeability Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005945 von Braun degradation reaction Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/16—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US18710588A | 1988-04-28 | 1988-04-28 | |
PCT/US1989/001689 WO1989010363A1 (en) | 1988-04-28 | 1989-04-26 | Fused polycyclic compounds, compositions, methods of manufacture and their use as paf antagonists, antihistamines and/or antiinflammatory agents |
Publications (3)
Publication Number | Publication Date |
---|---|
NO904666D0 NO904666D0 (no) | 1990-10-26 |
NO904666L NO904666L (no) | 1990-12-27 |
NO300972B1 true NO300972B1 (no) | 1997-08-25 |
Family
ID=22687612
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO904666A NO300972B1 (no) | 1988-04-28 | 1990-10-26 | Analogifremgangsmåte for fremstilling av terapeutisk aktive, kondenserte polysykliske forbindelser |
Country Status (17)
Country | Link |
---|---|
EP (2) | EP0339978B1 (fi) |
JP (1) | JP2511550B2 (fi) |
AT (1) | ATE141599T1 (fi) |
CA (1) | CA1341370C (fi) |
DE (1) | DE68926976T2 (fi) |
DK (1) | DK172717B1 (fi) |
ES (1) | ES2091195T3 (fi) |
FI (1) | FI96309C (fi) |
GR (1) | GR3021465T3 (fi) |
IL (1) | IL90102A (fi) |
MY (1) | MY106964A (fi) |
NO (1) | NO300972B1 (fi) |
NZ (1) | NZ228889A (fi) |
OA (1) | OA09321A (fi) |
SG (1) | SG44477A1 (fi) |
WO (1) | WO1989010363A1 (fi) |
ZA (1) | ZA893103B (fi) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2038417A1 (en) * | 1990-04-11 | 1991-10-12 | Yasuo Ito | Piperidine compounds, method for preparation thereof, and a pharmaceutical composition comprising the same |
US5470851A (en) * | 1990-06-27 | 1995-11-28 | Sankyo Company, Limited | Thiazolidinecarboxylic acid amide derivatives and their therapeutic uses |
EP0552292B1 (en) * | 1990-10-10 | 1995-06-21 | Schering Corporation | Substituted imidazobenzazepines and imidazopyridoazepines |
WO1992006970A1 (en) * | 1990-10-10 | 1992-04-30 | Schering Corporation | Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use |
FR2668150B1 (fr) * | 1990-10-17 | 1994-11-18 | Theramex | Nouveaux derives du terbutylphenyl 1-amino 4-hydroxybutane, leurs procedes de preparation et les compositions pharmaceutiques en renfermant. |
GB9102997D0 (en) * | 1991-02-13 | 1991-03-27 | Pfizer Ltd | Therapeutic agents |
JPH06508129A (ja) * | 1991-05-23 | 1994-09-14 | シェリング・コーポレーション | 新規のベンゾピリドピペリジリデン化合物、組成物、製造法および使用法 |
WO1993002081A1 (en) * | 1991-07-23 | 1993-02-04 | Schering Corporation | Novel benzopyrido piperylidene compounds, compositions, methods of manufacture and methods of use |
NO924963L (no) * | 1991-12-27 | 1993-06-28 | Sankyo Co | Pyridyltiazolidinkarboksylsyreamid-derivater og fremgangsmaate til fremstilling derav |
HUT71132A (en) * | 1992-03-27 | 1995-11-28 | Schering Corp | Bis-aryl-carbinol derivatives, pharmaceutical compositions containing them and process for producing |
EP0635012B1 (en) * | 1992-03-27 | 1996-07-10 | Schering Corporation | Unbridged bis-aryl carbinol derivatives, compositions and methods of use |
ES2042421B1 (es) * | 1992-05-22 | 1994-08-01 | Uriach & Cia Sa J | Procedimiento para la obtencion de la 8-cloro-11-*1-*(5-metil-3-piridil)metil*-4-piperidiliden*-6,11-dihidro-5h-benzo*5,6*ciclohepta*1,2-b*piridina. |
ATE198480T1 (de) * | 1993-07-13 | 2001-01-15 | Janssen Pharmaceutica Nv | Antiallergische imidazoazepine |
US6365588B1 (en) | 1993-10-15 | 2002-04-02 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5719148A (en) * | 1993-10-15 | 1998-02-17 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5721236A (en) * | 1993-10-15 | 1998-02-24 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5661152A (en) * | 1993-10-15 | 1997-08-26 | Schering Corporation | Tricyclic sulfonamide compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US6075025A (en) | 1993-10-15 | 2000-06-13 | Schering Corporation | Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5538986A (en) * | 1993-12-06 | 1996-07-23 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5574173A (en) * | 1993-12-06 | 1996-11-12 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5464840A (en) * | 1993-12-06 | 1995-11-07 | Schering Corporation | Tricyclic derivatives, compositions and methods of use |
US5700806A (en) * | 1995-03-24 | 1997-12-23 | Schering Corporation | Tricyclic amide and urea compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5684013A (en) * | 1995-03-24 | 1997-11-04 | Schering Corporation | Tricyclic compounds useful for inhibition of g-protein function and for treatment of proliferative diseases |
US5891872A (en) * | 1995-04-07 | 1999-04-06 | Schering Corporation | Tricyclic compounds |
US5712280A (en) * | 1995-04-07 | 1998-01-27 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5801175A (en) | 1995-04-07 | 1998-09-01 | Schering Corporation | Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases |
US5874442A (en) | 1995-12-22 | 1999-02-23 | Schering-Plough Corporation | Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease |
WO1998043638A1 (fr) * | 1997-03-27 | 1998-10-08 | Kyowa Hakko Kogyo Co., Ltd. | Agent therapeutique pour maladies auto-immunes |
US6225322B1 (en) * | 1997-06-17 | 2001-05-01 | Schering Corporation | Compounds useful for inhibition of farnesyl protein transferase |
BR0013935A (pt) * | 1999-09-13 | 2002-05-14 | Bridge Pharma Inc | IsÈmeros oticamente ativos de cetotifeno e metabólitos terapeuticamente ativos dos mesmos |
US8377967B2 (en) | 2008-01-30 | 2013-02-19 | Nippon Zoki Pharmaceutical Co., Ltd. | Piperidine derivative |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL137020C (fi) * | 1962-08-31 | |||
US3491103A (en) * | 1963-12-19 | 1970-01-20 | Sandoz Ag | Certain 4h-benzo(4,5)cyclohepta-(1,2-b) thiophenes |
FR91084E (fr) * | 1964-08-11 | 1968-04-05 | Sandoz Sa | Nouveaux benzo-cyclohepta-thiophènes et leur préparation |
US3458522A (en) * | 1967-05-17 | 1969-07-29 | Sandoz Ag | 4-piperidine substituted benzocycloheptaoxazoles and benzocycloheptathiazoles |
US3485846A (en) * | 1967-06-30 | 1969-12-23 | Eugene E Galantay | Benzocycloheptaimidazoles |
US3442903A (en) * | 1967-08-30 | 1969-05-06 | Sandoz Ag | Certain aminopropylidenebenzo(5,6)cyclohepta(1,2-d)thiazoles |
US3994915A (en) * | 1972-06-30 | 1976-11-30 | Sandoz, Inc. | Preparation of substituted oxazoles |
DE2640358A1 (de) * | 1976-09-08 | 1978-03-16 | Hoechst Ag | Thiazolidinderivate und verfahren zu ihrer herstellung |
US4173634A (en) * | 1979-02-23 | 1979-11-06 | E. R. Squibb & Sons, Inc. | Basically-substituted tricyclic pyrazoles useful as antiinflammatory agents |
DE3135250A1 (de) * | 1981-09-05 | 1983-03-17 | Basf Ag, 6700 Ludwigshafen | Tricyclische thiazolyloxamate, verfahren zu ihrer herstellung und diese enthaltende therapeutische mittel |
US4762843A (en) * | 1986-09-15 | 1988-08-09 | Warner-Lambert Company | Hetero [f] fused carbocyclic pyridines as dopaminergic agents |
US4826853A (en) * | 1986-10-31 | 1989-05-02 | Schering Corporation | 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use |
AU609808B2 (en) * | 1987-04-09 | 1991-05-09 | E.I. Du Pont De Nemours And Company | Insecticidal substituted indazoles |
ZA883659B (en) * | 1987-05-29 | 1989-01-25 | Merrell Dow Pharma | Cardiotonic tricyclic oxazolones |
-
1989
- 1989-04-26 JP JP1504829A patent/JP2511550B2/ja not_active Expired - Lifetime
- 1989-04-26 ES ES89304168T patent/ES2091195T3/es not_active Expired - Lifetime
- 1989-04-26 SG SG1996000742A patent/SG44477A1/en unknown
- 1989-04-26 CA CA000597848A patent/CA1341370C/en not_active Expired - Fee Related
- 1989-04-26 DE DE68926976T patent/DE68926976T2/de not_active Expired - Fee Related
- 1989-04-26 MY MYPI89000539A patent/MY106964A/en unknown
- 1989-04-26 EP EP89304168A patent/EP0339978B1/en not_active Expired - Lifetime
- 1989-04-26 EP EP89905353A patent/EP0412988A1/en active Pending
- 1989-04-26 ZA ZA893103A patent/ZA893103B/xx unknown
- 1989-04-26 AT AT89304168T patent/ATE141599T1/de not_active IP Right Cessation
- 1989-04-26 WO PCT/US1989/001689 patent/WO1989010363A1/en active IP Right Grant
- 1989-04-26 NZ NZ228889A patent/NZ228889A/xx unknown
- 1989-04-27 IL IL9010289A patent/IL90102A/en not_active IP Right Cessation
-
1990
- 1990-10-25 DK DK199002569A patent/DK172717B1/da active IP Right Grant
- 1990-10-26 NO NO904666A patent/NO300972B1/no not_active IP Right Cessation
- 1990-10-26 FI FI905281A patent/FI96309C/fi not_active IP Right Cessation
- 1990-10-26 OA OA59878A patent/OA09321A/xx unknown
-
1996
- 1996-10-24 GR GR960402820T patent/GR3021465T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
DK256990D0 (da) | 1990-10-25 |
DK172717B1 (da) | 1999-06-14 |
OA09321A (en) | 1992-09-15 |
DE68926976T2 (de) | 1997-02-27 |
ZA893103B (en) | 1989-12-27 |
MY106964A (en) | 1995-08-30 |
NZ228889A (en) | 1991-09-25 |
EP0339978A1 (en) | 1989-11-02 |
JP2511550B2 (ja) | 1996-06-26 |
JPH03504855A (ja) | 1991-10-24 |
SG44477A1 (en) | 1997-12-19 |
AU3535689A (en) | 1989-11-24 |
WO1989010363A1 (en) | 1989-11-02 |
GR3021465T3 (en) | 1997-01-31 |
IL90102A (en) | 1994-07-31 |
EP0339978B1 (en) | 1996-08-21 |
DE68926976D1 (de) | 1996-09-26 |
NO904666D0 (no) | 1990-10-26 |
NO904666L (no) | 1990-12-27 |
DK256990A (da) | 1990-12-17 |
EP0412988A1 (en) | 1991-02-20 |
FI96309B (fi) | 1996-02-29 |
CA1341370C (en) | 2002-06-18 |
ES2091195T3 (es) | 1996-11-01 |
ATE141599T1 (de) | 1996-09-15 |
FI905281A0 (fi) | 1990-10-26 |
FI96309C (fi) | 1996-06-10 |
IL90102A0 (en) | 1989-12-15 |
AU631795B2 (en) | 1992-12-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO300972B1 (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive, kondenserte polysykliske forbindelser | |
FI96690C (fi) | Menetelmä valmistaa terapeuttisesti aktiivista bentsopyridopiperidiini-, piperidylideeni- ja -piperatsiiniyhdistettä | |
NO179674B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive, heterosykliske N-oksidderivater av substituerte benzo[5,6Åsyklo-heptapyridiner | |
US4933353A (en) | Lipophilically-substituted piperidine oxadiazolyl compounds and their use in stimulating cognitive functions (II) | |
AU2002335031C1 (en) | Himbacine analogues as thrombin receptor antagonists | |
AU646878B2 (en) | Bis-benzo or benzopyrido cyclo hepta piperidene, piperidylidene and piperazine compounds and compositions | |
US5919805A (en) | Hetrocyclic compounds and their preparation and use | |
RU2248349C2 (ru) | Производные эфиров карбаминовой кислоты, их получение (варианты) и их применение в качестве лигандов метаботропных глутаматных рецепторов | |
JPH02500910A (ja) | ベンゾ〔5,6〕シクロヘプタピリジン類、組成物および使用法 | |
IE913571A1 (en) | Pyridine and pyridine N-oxide derivatives of diarylmethyl- piperidines or piperazines, compositions and use thereof | |
JP2011513476A (ja) | アミド−チオフェン化合物およびその使用 | |
IE912958A1 (en) | Heterocyclic compounds and their preparation and use | |
US5514687A (en) | Benzopyrido piperidylidene compounds, compositions, methods of manufacture and method of use | |
US3491103A (en) | Certain 4h-benzo(4,5)cyclohepta-(1,2-b) thiophenes | |
EP0642514B1 (en) | Bridged bis-aryl carbinol derivatives, compositions and methods of use | |
RU2611627C2 (ru) | Алкалоидный эфир и карбаматные производные и их медицинские композиции | |
US6613903B2 (en) | Modulators of protein tyrosine phosphatases (PTPases) | |
US5679692A (en) | Unbridged bis-aryl carbinol derivatives, compositions and methods of use | |
AU631795C (en) | Fused polycyclic compounds, compositions, methods of manufacture and their use as PAF antagonists, antihistamines and/or antiinflammatory agents | |
NO173062B (no) | Analogifremgangsmaate for fremstilling av terapeutisk aktive benzo(5,6)cykloheptapyridiner | |
NO175480B (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive benzopyridopiperidin-, benzopyridopiperidyliden- og benzopyridopiperazinforbindelser | |
NZ612688B2 (en) | (PYRIDIN-4-YL)BENZYLAMIDES AS ALLOSTERIC MODULATORS OF ALPHA 7 nAChR |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM1K | Lapsed by not paying the annual fees |
Free format text: LAPSED IN OCTOBER 2001 |